KEY's NITRO-DUR MARKETSHARE UP TO 45% OF TRANSDERMAL NITROGLYCERIN
KEY's NITRO-DUR MARKETSHARE UP TO 45% OF TRANSDERMAL NITROGLYCERIN Rxs written, the company said in its recently released first quarter financial results. Rxs for Nitro-Dur "were at record levels in the first quarter of 1984, reflecting a 90% increase in Rxs from year ago levels and a 10% increase from the fourth quarter of 1983," Key reported. The firm's other major project, Theo-Dur, continues to hold a 22% share of total bronchodilator Rxs, reflecting increases in total Rxs from the first quarter of 1983 for both Theo-Dur (up 21%) and Theo-Dur Sprinkle (up 141%), the company said. First quarter sales for the Miami-based firm were up 42.5% to $35.6 mil. accompanied by a 50.1% jump in net earnings to $4.8 mil. Key noted that operating income, which excludes research and license fee income, was up 61% this year from the same period last year. [For other firms reporting financials, see table on p. 18]. "The 42% sales increase in the first quarter represented a particularly impressive achievement in view of the heavy competitive pressures that we face, but we are especially pleased at the 50% growth in income," Key President Michael Jaharis declared. "The stronger growth in income reflected the continued improvements in manufacturing efficiencies that we have been able to achieve as we gain more experience in Nitro-Dur production." As a result, he added, Key's gross profit margin in the quarter was 68.4%, up 3.6% from the prior year.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth